latest news releases from the newsroom
EDAP TMS SA
EDAP TMS S.A. Closes $20 Million Placement to Fully Fund Its U.S. Clinical Studies
LYON, France, Nov. 5, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (Nasdaq:EDAP), the global leader in High Intensity Focused Ultrasound treatment of prostate cancer, announces that it has closed its capital raise with selected U.S. based qualified institutional buyers, pursuant to which the investors purchased US $20 million in Unsecured Convertible Debentures, convertible into EDAP's ordinary shares, to be delivered in the form of American Depository Receipts ("ADRs"). The Company expects this investment to fully fund EDAP's ongoing Phase II/III clinical studies of Ablatherm-HIFU at selected leading cancer treatment centers across the U.S. Eligibility criteria and center information can be found online at www.clinicaltrials.gov or at participating centers.
VirtualScopics Announces Record Level of New Contracts Signed and Awarded Totaling $13 Million
ROCHESTER, N.Y., Nov. 5, 2007 (PRIME NEWSWIRE) -- VirtualScopics, Inc. (Nasdaq:VSCP), a leading developer of image-based biomarker solutions to the pharmaceutical, biotechnology and medical device industries, announced today that year-to-date 2007 contracted agreements total $8.4 million plus an additional $4.6 million in awarded agreements awaiting signature. The 2007 agreements-to-date include 10 of the top 15 pharmaceutical, biotechnology and medical device companies and represent 47 new contracts and 39 additions to the scope of existing contracts. Of the newly signed and awarded contracts, 24% are Phase III studies, 65% are Phase I/II studies and 11% are research studies.